The prospects of minocycline in multiple sclerosis. Chen X, Ma X, Jiang Y, Pi R, Liu Y, Ma L J Neuroimmunol. 2011 Jun; 235(1-2):1-8. Epub 2011 May 11. PMID: 21565409. Abstract
Minocin US Food and Drug Administration Accessed on 29 Jul 2013 from http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/050649023lbl.pdf.
Minocycline Hydrochloride (1818) Mosby, Elsevier Inc., 2010 Accessed on 29 Jul 2013 from http://www3.us.elsevierhealth.com/DrugConsult/Top_200/Drugs/e1818.html.
ARESTIN® US Food and Drug Administration Accessed on 29 Jul 2013 from http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050781s012lbl.pdf.
DYNACIN (MINOCYCLINE) Par Pharmaceutical, 2010 Accessed on 29 Jul 2013 from http://www.parpharm.com/generics/index.php?option=com_products&product_id=49884009601&Itemid=90.
Warner Chilcott sells Vectrin product line to Medicis Evaluate, 21 Sep 1999 Accessed on 29 Jul 2013 from http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=29388.
Ximino US Food and Drug Administration Accessed on 29 Jul 2013 from http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=201922&DrugName=XIMINO&ActiveIngred=MINOCYCLINE%20HYDROCHLORIDE&SponsorApplicant=RANBAXY%20LABS%20LTD&ProductMktStatus=3&goto=Search.DrugDetails.
XIMINO (minocycline hydrochloride) capsule, extended release [Ranbaxy Laboratories Inc.] US National Library of Medicine, Jul 2012 Accessed on 29 Jul 2013 from http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6e7d2a2f-e4b2-4d12-8d5d-e1c3a832b35c.
ChemIDplus Advanced United States National Library of Medicine Accessed on 29 Jul 2013 from http://chem.sis.nlm.nih.gov/chemidplus/chemidheavy.jsp. Note: Compound name must be entered under "Substance Identification" and then "Names and Synonyms" selected to view synonyms.
Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brundula V, Rewcastle BN, Metz LM, Bernard CC, Yong WV Brain. 2002 Jun; 125(Pt 6):1297-308. PMID: 12023318. Abstract
Tetracyclines inhibit human synovial collagenase in vivo and in vitro. Greenwald RA, Golub LM, Lavietes B, Ramamurthy NS, Gruber B, Laskin RS, McNamara TF J Rheumatol. 1987 Feb; 14(1):28-32. PMID: 3033237. Abstract
Minocycline inhibits antigen processing for presentation to human T cells: additive inhibition with chloroquine at therapeutic concentrations. Kalish RS, Koujak S Clin Immunol. 2004 Dec; 113(3):270-7. PMID: 15507392. Abstract
The influence of tetracyclines on T cell activation. Kloppenburg M, Verweij CL, Miltenburg AM, Verhoeven AJ, Daha MR, Dijkmans BA, Breedveld FC Clin Exp Immunol. 1995 Dec; 102(3):635-41. PMID: 8536384. Abstract
The tetracycline derivative minocycline differentially affects cytokine production by monocytes and T lymphocytes. Kloppenburg M, Brinkman BM, de Rooij-Dijk HH, Miltenburg AM, Daha MR, Breedveld FC, Dijkmans BA, Verweij C Antimicrob Agents Chemother. 1996 Apr; 40(4):934-40. PMID: 8849255. Abstract
Combination treatment of Glatiramer Acetate and Minocycline affects phenotype expression of blood monocyte-derived dendritic cells in Multiple Sclerosis patients. Ruggieri M, Pica C, Lia A, Zimatore GB, Modesto M, Di Liddo E, Specchio LM, Livrea P, Trojano M, Avolio C J Neuroimmunol. 2008 Jul 15; 197(2):140-6. Epub 2008 Jun 13. PMID: 18555539. Abstract
Minocycline protects SH-SY5Y cells from 6-hydroxydopamine by inhibiting both caspase-dependent and -independent programmed cell death. Ossola B, Lantto TA, Puttonen KA, Tuominen RK, Raasmaja A, Männistö PT J Neurosci Res. 2012 Mar; 90(3):682-90. Epub 2011 Nov 23. PMID: 22108958. Abstract
Inhibition of autoimmune encephalomyelitis by a tetracycline. Popovic N, Schubart A, Goetz BD, Zhang S-C, Linington C, Duncan ID Ann Neurol. 2002 Feb; 51(2):215-23. PMID: 11835378. Abstract
Minocycline attenuates experimental autoimmune encephalomyelitis in rats by reducing T cell infiltration into the spinal cord. Nikodemova M, Lee J, Fabry Z, Duncan ID J Neuroimmunol. 2010 Feb 26; 219(1-2):33-7. Epub 2010 Jan 25. PMID: 20089316. Abstract
Effective combination of minocycline and interferon-beta in a model of multiple sclerosis. Giuliani F, Fu S A, Metz LM, Yong WV J Neuroimmunol. 2005 Aug; 165(1-2):83-91. PMID: 15958276. Abstract
Combined treatment with minocycline and prednisone attenuates experimental autoimmune encephalomyelitis in C57 BL/6 mice. Chen X, Hu X, Zou Y, Pi R, Liu M, Wang T, Zheng X, Liu M, Lin M, Liu P, et al. J Neuroimmunol. 2009 May 29; 210(1-2):22-9. Epub 2009 Apr 02. PMID: 19344957. Abstract
Combined treatment with atorvastatin and minocycline suppresses severity of EAE. Luccarini I, Ballerini C, Biagioli T, Biamonte F, Bellucci A, Rosi M C, Grossi C, Massacesi L, Casamenti F Exp Neurol. 2008 May; 211(1):214-26. Epub 2008 Feb 14. PMID: 18346732. Abstract
Minocycline down-regulates MHC II expression in microglia and macrophages through inhibition of IRF-1 and protein kinase C (PKC)alpha/betaII. Nikodemova M, Watters JJ, Jackson SJ, Yang SK, Duncan ID J Biol Chem. 2007 May 18; 282(20):15208-16. Epub 2007 Mar 29. PMID: 17395590. Abstract
Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Yrjänheikki J, Keinänen R, Pellikka M, Hökfelt T, Koistinaho J Proc Natl Acad Sci U S A. 1998 Dec 22; 95(26):15769-74. PMID: 9861045. Abstract
Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. Tikka T, Fiebich BL, Goldsteins G, Keinanen R, Koistinaho J J Neurosci. 2001 Apr 15; 21(8):2580-8. PMID: 11306611. Abstract
Multiple neuroprotective mechanisms of minocycline in autoimmune CNS inflammation. Maier K, Merkler D, Gerber J, Taheri N, Kuhnert AV, Williams SK, Neusch C, Bähr M, Diem R Neurobiol Dis. 2007 Mar; 25(3):514-25. Epub 2007 Jan 18. PMID: 17239606. Abstract
Minocycline reduces gingival collagenolytic activity during diabetes. Preliminary observations and a proposed new mechanism of action. Golub LM, Lee HM, Lehrer G, Nemiroff A, McNamara TF, Kaplan R, Ramamurthy NS J Periodontal Res. 1983 Sep; 18(5):516-26. PMID: 6315909. Abstract
Antioxidant properties of minocycline: neuroprotection in an oxidative stress assay and direct radical-scavenging activity. Kraus RL, Pasieczny R, Lariosa-Willingham K, Turner MS, Jiang A, Trauger JW J Neurochem. 2005 Aug; 94(3):819-27. PMID: 16033424. Abstract
Minocycline chelates Ca2+, binds to membranes, and depolarizes mitochondria by formation of Ca2+-dependent ion channels. Antonenko YN, Rokitskaya TI, Cooper AJL, Krasnikov BF J Bioenerg Biomembr. 2010 Apr; 42(2):151-63. Epub 2010 Feb 24. PMID: 20180001. Abstract
Minocycline attenuates iron neurotoxicity in cortical cell cultures. Chen-Roetling J, Chen L, Regan RF Biochem Biophys Res Commun. 2009 Aug 21; 386(2):322-6. Epub 2009 Jun 10. PMID: 19523448. Abstract
Minocycline-induced attenuation of iron overload and brain injury after experimental intracerebral hemorrhage. Zhao F, Hua Y, He Y, Keep RF, Xi G Stroke. 2011 Dec; 42(12):3587-93. Epub 2011 Oct 13. PMID: 21998050. Abstract
Proteomic analysis of the anti-inflammatory action of minocycline. Dunston CR, Griffiths HR, Lambert PA, Staddon S, Vernallis AB Proteomics. 2011 Jan; 11(1):42-51. Epub 2010 Dec 06. PMID: 21182193. Abstract
Minocycline attenuates experimental colitis in mice by blocking expression of inducible nitric oxide synthase and matrix metalloproteinases. Huang T-Y, Chu H-C, Lin Y-L, Lin C-K, Hsieh T-Y, Chang W-K, Chao Y-C, Liao C-L Toxicol Appl Pharmacol. 2009 May 15; 237(1):69-82. Epub 2009 Mar 10. PMID: 19285099. Abstract
Minocycline in Clinically Isolated Syndromes (CIS) and Early Single Relapse Multiple Sclerosis (MS) ClinicalTrials.gov, 21 Mar 2012 Accessed on 30 Jul 2013 from http://www.clinicaltrials.gov/ct2/show/NCT00666887.
Safety and Efficacy Study of Copaxone Administered in Combination With Minocycline ClinicalTrials.gov, 11 Apr 2011 Accessed on 30 Jul 2013 from http://www.clinicaltrials.gov/ct2/show/NCT00203112.
Glatiramer acetate in combination with minocycline in patients with relapsing--remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial. Metz LM, Li D, Traboulsee A, Myles ML, Duquette P, Godin J, Constantin M, Yong VW, GA/minocycline study investigators Mult Scler. 2009 Oct; 15(10):1183-94. Epub 2009 Sep 23. PMID: 19776092. Abstract
Pilot study of minocycline in relapsing-remitting multiple sclerosis. Zhang Y, Metz LM, Yong WV, Bell RB, Yeung M, Patry DG, Mitchell RJ Can J Neurol Sci. 2008 May; 35(2):185-91. PMID: 18574932. Abstract
Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Metz LM, Zhang Y, Yeung M, Patry DG, Bell RB, Stoian CA, Yong WV, Patten SB, Duquette P, Antel JP, et al. Ann Neurol. 2004 May; 55(5):756. PMID: 15122721. Abstract
Minocycline treatment for rheumatoid arthritis: an open dose finding study. Breedveld FC, Dijkmans BA, Mattie H J Rheumatol. 1990 Jan; 17(1):43-6. PMID: 2313671. Abstract
Treatment of resistant rheumatoid arthritis with minocycline: an open study. Langevitz P, Bank I, Zemer D, Book M, Pras M J Rheumatol. 1992 Oct; 19(10):1502-4. PMID: 1334514. Abstract
Minocycline in active rheumatoid arthritis. A double-blind, placebo-controlled trial. Kloppenburg M, Breedveld FC, Terwiel JP, Mallee C, Dijkmans BA Arthritis Rheum. 1994 May; 37(5):629-36. PMID: 8185689. Abstract
Minocycline in rheumatoid arthritis. A 48-week, double-blind, placebo-controlled trial. MIRA Trial Group. Tilley BC, Alarcón GS, Heyse SP, Trentham DE, Neuner R, Kaplan DA, Clegg DO, Leisen JC, Buckley L, Cooper SM, et al. Ann Intern Med. 1995 Jan 15; 122(2):81-9. PMID: 7993000. Abstract
Efficacy of minocycline in acute ischemic stroke: a single-blinded, placebo-controlled trial. Padma Srivastava MV, Bhasin A, Bhatia R, Garg A, Gaikwad S, Prasad K, Singh M B, Tripathi M Neurol India. 2012 Jan-Feb; 60(1):23-8. PMID: 22406775. Abstract
Results of a phase II placebo-controlled randomized trial of minocycline in acute spinal cord injury. Casha S, Zygun D, McGowan DM, Bains I, Yong WV, Hurlbert JR Brain. 2012 Apr; 135(Pt 4):1224-36. PMID: 22505632. Abstract
A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. NINDS NET-PD Investigators Neurology. 2006 Mar 14; 66(5):664-71. Epub 2006 Feb 15. PMID: 16481597. Abstract
Neuroprotection in Huntington's disease: a 2-year study on minocycline. Bonelli RM, Hödl AK, Hofmann P, Kapfhammer H-P Int Clin Psychopharmacol. 2004 Nov; 19(6):337-42. PMID: 15486519. Abstract
Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Gordon PH, Moore DH, Miller RG, Florence JM, Verheijde JL, Doorish C, Hilton JF, Spitalny MG, MacArthur RB, Mitsumoto H, et al. Lancet Neurol. 2007 Dec; 6(12):1045-53. Epub 2007 Nov 05. PMID: 17980667. Abstract
Perth scientists embark on stroke therapy approach ScienceNetwork, Western Australia, 12 Aug 2013 Accessed on 13 Aug 2013 from http://www.sciencewa.net.au/topics/health-a-medicine/item/2324-perth-scientists-embark-on-stroke-therapy-approach.html.
Interferon β-secreting mesenchymal stem cells combined with minocycline attenuate experimental autoimmune encephalomyelitis. Hou Y, Ryu C H, Jun J A, Kim S M, Jeong C H, Jeun S-S J Neuroimmunol. 2014 Jun 20. PMID: 25005115. Abstract
Modulation of Sox10, HIF-1α, Survivin, and YAP by Minocycline in the Treatment of Neurodevelopmental Handicaps following Hypoxic Insult. Li Q, Tsuneki M, Krauthammer M, Couture R, Schwartz M, Madri JA Am J Pathol. 2015 Sep; 185(9):2364-78. Epub 2015 Jul 22. PMID: 26209807. Abstract
Tried-and-True Antibiotic May Block Conversion to MS Fiore K, MedPage Today, 10 Oct 2015 Accessed on 13 Oct 2015 from http://www.medpagetoday.com/clinical-context/MultipleSclerosis/54038.
Minocycline added to subcutaneous interferon β-1a in multiple sclerosis: randomized RECYCLINE study. Sørensen PS, Sellebjerg F, Lycke J, Färkkilä M, Créange A, Lund CG, Schluep M, Frederiksen JL, Stenager E, Pfleger C, et al. Eur J Neurol. 2016 Feb 5. PMID: 26848561. Abstract
Minocycline as add-on to Interferon Beta-1a [IFN Beta-1a] (Rebif®) in Relapsing-Remitting Multiple Sclerosis [RRMS] (RECYCLINE) ClinicalTrials.gov, 2 Dec 2013 Accessed on 12 Feb 2016 from https://www.clinicaltrials.gov/ct2/show/NCT01134627.
